← Back to Search

89Zr-DFO-trastuzumab for Esophageal Cancer

N/A
Waitlist Available
Led By Neeta Pandit-Taskar, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This trial is testing a new way to deliver cancer drugs. The first group of patients is helping the investigators learn when to take pictures and how to monitor the drug in the blood. The second group of patients will just receive the injection and be asked to return for a picture 5-8 days later.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Toxicity
feasibility
Secondary outcome measures
metabolite analysis

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET Imaging With 89Zr-DFO-TrastuzumabExperimental Treatment2 Interventions
Patients will receive 5 mCi + 0.5 mCi of 89Zr-DFO-trastuzumab given IV over 5-10 min. Injection of cold trastuzumab will be mixed with 89Zr-DFO-trastuzumab so that total mass is equal to 50 mg [1]. In the first ten patients we wish to obtain normal organ dosimetry, pharmacokinetics & determine optimal imaging time, therefore these patients will undergo imaging at 4 time points post injection, whole body counts & blood draws. Subsequent patients will receive the antibody & will only undergo imaging at a single time point (based on the first 10 patients) & will not have whole body counts or serial bloods for pharmacokinetics. The administration of 89Zr-DFO-trastuzumab to patients undergoing a second study will be identical as for their baseline study. Patients undergoing a second injection will only have one scan that will be performed within 1 day before or 2 days after their optimum imaging time point, determined from their baseline imaging study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET imaging
2005
Completed Phase 3
~670
89Zr-DFO-trastuzumab
2013
N/A
~40

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,933 Previous Clinical Trials
585,586 Total Patients Enrolled
Neeta Pandit-Taskar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
9 Previous Clinical Trials
308 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any open enrollments for this experiment?

"The records on clinicaltrials.gov evidence that this medical trial, first posted in December 2013 and revised recently in 2021, is not currently seeking out prospective participants. Nonetheless, there are 7 active studies recruiting patients at the present time."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
2013. "PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02023996.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top